Comparison of serum beta-2 microglobulin level between dialysis patients on high flux hemodialysis versus hemodiafiltration

BACKGROUND: End-stage renal disease (ESRD) is a serious health issue that may have life-threatening consequences for those who have it. The buildup of medium molecular weight solutes, most notably beta-2 microglobulin (B2M), is one of the main consequences of end-stage renal disease (ESRD). Serum beta-2 microglobulin levels in high flux hemodialysis and hemodiafiltration patients will be compared in this research.METHODS: Samples came from Basrah Teaching Hospital. All research patients gave written informed consent. This research comprised 200 end-stage renal disease patients aged 20-70. Disposable syringes were used to draw 5 mL of venous blood from each patient in plain tubes without anticoagulant and identify them with their name and date. The samples were processed promptly. Urea, creatinine, blood gases, complete blood count, calcium, phosphate, parathyroid hormone, Serum beta-2 microglobulin, potassium, sodium, and bicarbonate were measured in blood serum after centrifugation at 10,000 rpm for 5 min at 4°C.RESULTS: Patients under hemodiafiltration (HDF) showed a notable decrease in B2M compared to those under hemodialysis (HD) and a longer dialysis period. Both HD and HDF patient groups exhibited a significant positive correlation between B2M and potassium, with no significant correlation between B2M and other factors like age or ferritin. Notably, HD was more linked with hypertension, while HDF was more associated with diabetes mellitus (DM).CONCLUSIONS: The data that were obtained in this study supported the benefits of HDF in B2M clearance, with patient conditions influencing dialysis choice. The strong B2M-potassium link in both modalities underscored the importance of diligent monitoring.